论文部分内容阅读
目的:观察PEG-IFN-2a联合蒙药红花-13味散治疗CHB的临床疗效。方法:40例CHB患者,皮下注射PEGIFN-2a,135μg,1次/wk,同时服用蒙药红花-13味散,3g,2次/d,疗程24wk。结果:治疗24 wk后测定AL、AST、TBIL和GGT,结果分别为33.54±17.26Uu/L、36.48±20.83u/L、9.61±3.90μmol/L和26.26±14.1 u/L,显著低于治疗前70.10±90.76 u/L(P<0.05)、72.93±103.13 u/L(P<0.05)、35.8±59.68μmol/L(P<0.05)和99.6±148.68 u/L(P<0.05),差异均具有显著性意义。治疗过程中均未见明显不良反应。结论:观察PEG-IFN-2a联合蒙药红花-13味散可以有效地改善肝功能。
Objective: To observe the clinical efficacy of PEG-IFN-2a in combination with Mongolian Mongolian safflower-13 powder in the treatment of CHB. Methods: Forty patients with CHB were injected subcutaneously with PEGIFN-2a, 135μg and 1 time / wk. Mongolian medicine safflower-13 powder, 3g and 2 times daily were given for 24 weeks. Results: AL, AST, TBIL and GGT were measured after 24 weeks of treatment, the results were 33.54 ± 17.26Uu / L, 36.48 ± 20.83u / L, 9.61 ± 3.90μmol / L and 26.26 ± 14.1u / L, (P <0.05), pre-70.10 ± 90.76 u / L (P <0.05), 72.93 ± 103.13 u / L, 35.8 ± 59.68μmol / L and 99.6 ± 148.68 u / L respectively All have significant significance. No obvious adverse reactions during treatment. Conclusion: Observing PEG-IFN-2a combined with Mongolian drug safflower-13 powder can effectively improve liver function.